James Marks, MD, PhD

James Marks, MD, PhD

Professor

Education

M.D., 1979 - School of Medicine, University of California, San Francisco
Residency, - School of Medicine, University of California, San Francisco

Publications

San Francisco's Citywide COVID-19 Response: Strategies to Reduce COVID-19 Severity and Health Disparities, March 2020 Through May 2022.

Sachdev DD, Petersen M, Havlir DV, Schwab J, Enanoria WTA, Nguyen TQ, Mercer MP, Scheer S, Bennett A, Tenner AG, Marks JD, Bobba N, Philip S, Colfax G

A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice.

Fan Y, Lou J, Tam CC, Wen W, Conrad F, Leal da Silva Alves P, Cheng LW, Garcia-Rodriguez C, Farr-Jones S, Marks JD

Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F.

Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD

Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model.

Tomic MT, Farr-Jones S, Syar ES, Niemuth N, Kobs D, Hackett MJ, Espinoza Y, Martinez Z, Pham K, Snow DM, Marks JD, Cobb RR

A Four-Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotypes C and D.

Garcia-Rodriguez C, Yan S, Geren IN, Knopp KA, Dong J, Sun Z, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD

A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model.

Snow DM, Cobb RR, Martinez J, Finger-Baker I, Collins L, Terpening S, Syar ES, Niemuth N, Kobs D, Barnewall R, Farr-Jones S, Marks JD, Tomic MT

Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.

Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison C, Drummond DC

Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β.

Campbell MG, Cormier A, Ito S, Seed RI, Bondesson AJ, Lou J, Marks JD, Baron JL, Cheng Y, Nishimura SL

The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA.

Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.

Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A

Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination Against Botulinum C and D Neurotoxins.

Snow DM, Riling K, Kimbler A, Espinoza Y, Wong D, Pham K, Martinez Z, Kraus CN, Conrad F, Garcia-Rodriguez C, Cobb RR, Marks JD, Tomic MT

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats.

Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT

Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.

Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.

Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC

Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine.

Lou J, Marks JD

Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.

Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron JL, Nishimura SL

Antibody engineering to improve manufacturability.

Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH

A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.

Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD

A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.

Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD

Discovery of internalizing antibodies to basal breast cancer cells.

Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD

A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.

Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.

Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA

White Matter Injury and General Movements in High-Risk Preterm Infants.

Peyton C, Yang E, Msall ME, Adde L, Støen R, Fjørtoft T, Bos AF, Einspieler C, Zhou Y, Schreiber MD, Marks JD, Drobyshevsky A

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.

Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS

Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety.

Krombach JW, Marks JD, Dubowitz G, Radke OC

Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5.

Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA

Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.

Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD

Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution.

Krombach JW, Edwards WA, Marks JD, Radke OC

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN

Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.

Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD

TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease.

Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL

A fully human scFv phage display library for rapid antibody fragment reformatting.

Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM

Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.

Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL

Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.

D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK

High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display.

Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y

Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments.

Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM

Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.

Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM

Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.

Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks JD, Wu AM

Selective targeting of TGF-β activation to treat fibroinflammatory airway disease.

Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL

Identifying blood-brain-barrier selective single-chain antibody fragments.

Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV

Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A

RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.

Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S

Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.

Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T

Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism.

Jones RGA, Marks JD

Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor.

Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD, Denny CT

Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays.

Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM

Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein.

Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD

N-Terminal labeling of filamentous phage to create cancer marker imaging agents.

Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB

An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.

McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM

Selection and characterization of cell binding and internalizing phage antibodies.

Zhou Y, Zhao L, Marks JD

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD

A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test.

Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG

Building and characterizing antibody-targeted lipidic nanotherapeutics.

Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC

Discovery of internalizing antibodies to tumor antigens from phage libraries.

Zhou Y, Marks JD

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG

Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies.

Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR

Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SKH

Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.

Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD

Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β.

Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL

Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.

Gray SA, Barr JR, Kalb SR, Marks JD, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.

Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP

Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.

Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK

Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.

Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD

Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens.

Zhou Y, Zou H, Zhang S, Marks JD

Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.

Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR

TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS.

Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M

Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.

Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA

An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.

Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM

Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating.

Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks JD

Tumor detection by imaging proteolytic activity.

Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS

A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region.

Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB

Antibody protection against botulinum neurotoxin intoxication in mice.

Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD

Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity.

Ozanich RM, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks JD, Lou J, Grate JW

Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies.

Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks JD, Bruckner-Lea CJ

Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.

Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR

Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format.

Grate JW, Warner MG, Ozanich RM, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC, Lind MA, Lou J, Marks JD, Bruckner-Lea CJ

Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC

Identification of target and function specific antibodies for effective drug delivery.

Zhou Y, Marks JD

Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Dimitrov DS, Marks JD

Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.

Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP

Development of human single-chain antibodies against SARS-associated coronavirus.

Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW

Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.

Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP

Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids.

Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks JD, Xie G, Brettin TS

Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy.

Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.

Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B

Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.

Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D

Affinity thresholds for membrane fusion triggering by viral glycoproteins.

Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW

Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD

Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD

Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.

Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD

Genetic diversity among Botulinum Neurotoxin-producing clostridial strains.

Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks JD

Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.

Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N, Park JW, Marks JD, Benz CC, Kirpotin DB

Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.

Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD

A novel assay for monitoring internalization of nanocarrier coupled antibodies.

Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD

Using phage display to select antibodies recognizing post-translational modifications independently of sequence context.

Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks JD, Bertozzi CR, Bradbury AR

A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.

Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW

Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies.

Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ

Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases.

Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB

Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.

Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.

Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM

Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.

Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD

Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD

Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.

Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD

Infectious Disease and Bioterrorism.

Hughes SC, Marks JD

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.

Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP

Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.

Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL

Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.

Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB

Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42.

Manoutcharian K, Acero G, Munguia ME, Becerril B, Massieu L, Govezensky T, Ortiz E, Marks JD, Cao C, Ugen K, Gevorkian G

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.

Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM

Medical aspects of biologic toxins.

Marks JD

Development of ligand-targeted liposomes for cancer therapy.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC

Antibodies from phage antibody libraries.

Bradbury AR, Marks JD

Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies.

Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, Foster KA

Yeast mating for combinatorial Fab library generation and surface display.

Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ

Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.

Marks JD

Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron.

Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks JD, Santoro C

Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.

Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD

Antibody affinity maturation by chain shuffling.

Marks JD

PCR cloning of human immunoglobulin genes.

Marks JD, Bradbury A

Selection of human antibodies from phage display libraries.

Marks JD, Bradbury A

Selection of internalizing antibodies for drug delivery.

Marks JD

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW

Predicting antigenic peptides suitable for the selection of phage antibodies.

Pavlik P, Siegel RW, Marzari R, Sblattero D, Verzillo V, Collins C, Marks JD, Bradbury A

The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies.

Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD

Phage versus phagemid libraries for generation of human monoclonal antibodies.

O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD

Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.

Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC

The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies.

Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A

Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.

Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD

Phage-display antibody detection of Chlamydia trachomatis-associated antigens.

Lindquist EA, Marks JD, Kleba BJ, Stephens RS

Towards proteome-wide production of monoclonal antibody by phage display.

Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD

Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.

Mullaney BP, Pallavicini MG, Marks JD

Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.

Li X, Stuckert P, Bosch I, Marks JD, Marasco WA

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM

Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity.

McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM

Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin.

Sheridan RE, Deshpande SS, Amersdorfer P, Marks JD, Smith T

Expression of single-chain Fv-Fc fusions in Pichia pastoris.

Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD

Antibodies to human fetal erythroid cells from a nonimmune phage antibody library.

Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks JD

Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.

Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC

Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells.

Marshall KW, Marks JD

Lung collapse during low tidal volume ventilation in acute respiratory distress syndrome.

Kallet RH, Siobal MS, Alonso JA, Warnecke EL, Katz JA, Marks JD

Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

Nielsen UB, Adams GP, Weiner LM, Marks JD

Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose.

Liu B, Marks JD

Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics.

Siegel RW, Allen B, Pavlik P, Marks JD, Bradbury A

Measuring intra-esophageal pressure to assess transmural pulmonary arterial occlusion pressure in patients with acute lung injury: a case series and review.

Kallet RH, Katz JA, Pittet JF, Ghermey J, Siobal M, Alonso JA, Marks JD

Selection of tumor-specific internalizing human antibodies from phage libraries.

Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD

Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules.

Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW

The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM).

Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD

Improved flow and pressure capabilities of the Datex-Ohmeda SmartVent anesthesia ventilator.

Katz JA, Kallet RH, Alonso JA, Marks JD

Initial severity of metabolic acidosis predicts the development of acute lung injury in severely traumatized patients.

Eberhard LW, Morabito DJ, Matthay MA, Mackersie RC, Campbell AR, Marks JD, Alonso JA, Pittet JF

Phage libraries for generation of anti-botulinum scFv antibodies.

Amersdorfer P, Marks JD

Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.

Cirino NM, Sblattero D, Allen D, Peterson SR, Marks JD, Jackson PJ, Bradbury A, Lehnert BE

Synthesis of Rh Fv phage-antibodies using VH and VL germline genes.

Hughes-Jones NC, Bye JM, Gorick BD, Marks JD, Ouwehand WH

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM

Targeted gene delivery to mammalian cells by filamentous bacteriophage.

Poul MA, Marks JD

Toward selection of internalizing antibodies from phage libraries.

Becerril B, Poul MA, Marks JD

Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries.

McCall AM, Amoroso AR, Sautès C, Marks JD, Weiner LM

Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens.

Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD, Lindqvist E

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD

Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients.

Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD

Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM

Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.

Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD

Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.

Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC

Human autoimmune anti-proteinase 3 scFv from a phage display library.

Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks JD, Lockwood CM, Ouwehand WH

Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.

Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD

Phage libraries--a new route to clinically useful antibodies.

Marks C, Marks JD

Identification of functional and structural amino-acid residues by parsimonious mutagenesis.

Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD

Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection.

Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD

Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections.

Schier R, Marks JD

Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries.

Finnern R, Bye JM, Dolman KM, Zhao MH, Short A, Marks JD, Lockwood MC, Ouwehand WH

In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.

Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM

Characterization of human blood group scFv antibodies derived from a V gene phage-display library.

Hughes-Jones NC, Gorick BD, Bye JM, Finnern R, Scott ML, Voak D, Marks JD, Ouwehand WH

In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation.

Figini M, Marks JD, Winter G, Griffiths AD

Fiberoptic-aided endobronchial intubation.

Marks JD

Performing fiberoptic endotracheal intubation: clinical aspects.

Stackhouse RA, Marks JD, Bainton CR

Practical aspects of fiberoptic laryngobronchoscopy.

Marks JD, Bainton CR

The humoral immune response against blood group antigens at the molecular level.

Ouwehand WH, Bye JM, Gorick BD, Marks JD, Timmers E, Griffin HM, Finnern R, Hughes-Jones N

Human antibody fragments specific for human blood group antigens from a phage display library.

Marks JD, Ouwehand WH, Bye JM, Finnern R, Gorick BD, Voak D, Thorpe SJ, Hughes-Jones NC, Winter G

Human anti-self antibodies with high specificity from phage display libraries.

Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC

Building antibodies from their genes.

Hoogenboom HR, Marks JD, Griffiths AD, Winter G

Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift.

Bye JM, Carter C, Cui Y, Gorick BD, Songsivilai S, Winter G, Hughes-Jones NC, Marks JD

Structural repertoire of the human VH segments.

Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G

The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops.

Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G

Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.

Marks JD, Hoogenboom HR, Griffiths AD, Winter G

By-passing immunization: building high affinity human antibodies by chain shuffling.

Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G

An artificial immune system for making antibodies.

Marks JD, Winter G

By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G

Airway management for trauma patients with potential cervical spine injuries.

Hastings RH, Marks JD

Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes.

Marks JD, Tristem M, Karpas A, Winter G

Cloning and sequencing of human lambda immunoglobulin genes by the polymerase chain reaction.

Songsivilai S, Bye JM, Marks JD, Hughes-Jones NC

Factors affecting perioperative pulmonary function in acute respiratory failure.

Biery DR, Marks JD, Schapera A, Autry M, Schlobohm RM, Katz JA

Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome.

Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA

Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration.

Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF

Perioperative pulmonary function in acute respiratory failure: effect of ventilator type and gas mixture.

Schapera A, Marks JD, Minagi H, Goodman P, Katz JA

Pressure and flow limitations of anesthesia ventilators.

Marks JD, Schapera A, Kraemer RW, Katz JA

Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock.

Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF

Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery.

Hansen RM, Viquerat CE, Matthay MA, Wiener-Kronish JP, DeMarco T, Bahtia S, Marks JD, Botvinick EH, Chatterjee K

Inspiratory work with and without continuous positive airway pressure in patients with acute respiratory failure.

Katz JA, Marks JD

Effect of increases in lung volume on clearance of aerosolized solute from human lungs.

Marks JD, Luce JM, Lazar NM, Wu JN, Lipavsky A, Murray JF

The inhibitory action of a phenothiazine derivative on the hexosemonophosphate dehydrogenases of adrenal cortex.

MARKS JD, ROESKY N, CARVER MJ